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Abstract 
Background: Research over the last twenty years has yielded much insight into pancreatic 
cancer biology, but it has neither improved diagnostics methods nor the way of treatment. 
The question remains as to what the critical deciding factor is in making pancreatic cancer 
such an aggressive disease. 
Methods: Pancreatic tumor tissue came from 36 patients. To assess lymphatic vessels color 
lymphangiography and  immunohistochemistry  were  used.  Activity  of  matrix  metallopro-
teinases was studied with gel and in situ zymography. Expression of growth factors and infil-
trating immune cells were investigated using immunohistochemistry. 
Results: Our study revealed that the structures that correspond to lymphatic vessels were not 
observed in tumor center but only at the edge of the tumor. All studied growth factors were 
present in tumor tissue. We found that the difference in expression between G2 and G3 stage 
was statistically relevant in cases of c-Met receptor. Inflammatory cells were present around 
neoplastic glands and also strongly around nerves infiltrated by cancer cells. The number of 
infiltrating macrophages in tumor tissue was significantly higher in group with metastases to 
lymph nodes. 
Conclusion: We showed two factors that influence pancreatic cancer progression and inva-
sion: c-Met receptors and macrophages infiltrating tumor tissue. Based on our analysis, this 
indicates that epithelial-mesenchymal transition might be crucial in the progression of pan-
creatic cancer. 
Key words: pancreatic cancer, growth factors, matrix metalloproteinases, lymphangiogenesis, mi-
croenvironment. 
Introduction 
Pancreatic  adenocarcinoma  remains  one  of  the 
deadliest cancers. 1- and 5-year relative survival rates 
are 25% and 6%, respectively1. The surgical interven-
tion remains main possibility of treatment because 
chemotherapy and radiotherapy has minimal impact 
on long-term survival. Research over the last  twenty 
years has yielded much insight into pancreatic cancer 
biology,  but  it  has  neither  improved  diagnostics 
methods nor the way of treatment. The question r e-
mains as to what t he critical deciding factor is in 
making pancreatic cancer such an aggressive disease.  
It was shown in recent years that the tumor m i-
croenvironment plays a critical role in tumor pr o-
gression2.  In pancreatic tumors this  microenviro n-
ment  is  particularly  het erogeneous.  It  consists  of 
dense fibrotic stroma with cancer cells, stellate cells, 
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infiltrating inflammatory cells and the remains of the 
proper structure of the pancreas. These cells are the 
source  of  various  growth  factors:  FGF,  EGF, 
PDGF-BB,  HGF  as  well  as  proangiogenic  factors: 
VEGF,  VEGF  C  and  their  receptors.  The  fibroblasts 
present in the tumor's tissue are responsible for the 
production of collagen and fibronectin which increase 
the chemoresistance of the tumor. Because of abun-
dant fibrotic tissue, the tumor environment is strongly 
hypoxic3,4. These all factors contribute to the disease's 
aggressive nature and occurrence of early metastases. 
Infiltrating inflammatory cells are a rich source 
of  factors  influencing  tumor  growth,  invasion  and 
metastases.  Macrophages  are  of  particular  interest. 
Their role in the tumor's environment has been stud-
ied in recent years5. It is known that they are a rich 
source of growth factors that stimulate cell prolifer a-
tion like EGF, PDGF-BB, HGF and TGF β. Further-
more  they  also  produce  matrix  metalloproteinase-9 
(MMP9)  which  takes  part  in  various  essential  pro-
cesses like tissue remodeling, angiogenesis, epitheli-
al-mesenchymal  transition  and  activating  growth 
factors6. 
As early lymph node metastases are hallmarks of 
pancreatic cancer lymphatic vessels, they are consi d-
ered as the main route for the spread of pancreatic 
cancer. Examining lymphatic vessels makes possible 
evaluation  of  lymphangiogenesis  inside  tumor.  In 
some type of cancer7,8 there is a clear evidence linking 
lymphatic vessels and lymph node metastases, how-
ever pancreatic cancer reports on this topic are con-
tradictory9,10. 
The  aim  of  our  study  was  to  investigate  three 
points that may have an influence on the development 
of  the  tumor:  expression  of  growth  factors,  inflam-
matory cells infiltration and lymphangiogenesis.  
Materials and method 
Patients and specimen collection 
Pancreatic tissue samples were collected from 36 
patients  who  underwent  surgical  resection  due  to 
pancreatic  cancer.  Tissues  were  collected  based  on 
protocol  approved  by  the  Bioethics  Committee  of 
Warsaw Medical University. Tumors were classified 
according to TNM staging and tumor grade (Table 1).  
For  protein  isolation,  the  samples  were  frozen 
and stored at -20 °C until they were used. Samples for 
immunohistochemical analysis with dimensions of 5 x 
5 x 5 mm were frozen for 45 seconds in acetone using 
dry ice at a temperature of -70°C and stored at -80° C. 
Color lymphangiography 
The analysis was conducted as described previ-
ously11. In brief, a tissue fragment was injected with 
1ml of Paris blue paint suspension in chloroform u n-
der low pressure. The injected tissue was fixed in 5% 
formalin for 1 day and dehydrated for 6 days in turn 
to 60% 70%, 80%, 96% (two days), 100% ethanol. Then 
tissue was then placed in methyl salicylate. After at 
least 3 days it was cut into thick slices and examined 
under stereomicroscope at 100x magnification.  
 
Table 1. Staging of tumors obtained from patients. 
Parameter  Number of tumors (total n = 36) 
T stage   
T1  3 
T2  6 
T3  25 
T4  2 
N stage   
N0  13 
N1  20 
N1a  2 
N1b  1 
M stage   
M0  33 
M1  3 
Tumor grading   
G1  4 
G2  16 
G3  16 
 
 
Immunohistochemistry 
Frozen tissue from pancreatic cancer was cryocut 
into  5µm  sections  and  used  for  analysis.  The  Dako 
REAL™  EnVision™  Detection  System,  Peroxi-
dase/DAB+,  Rabbit/Mouse  was  used  for  im-
munostaining. After being dried in room temperature, 
the slides were fixed with acetone for 10 min. Then 
they were incubated for 5 min Dual Endogenous En-
zyme Block (Dako, Glostrup, Denmark). The sections 
were  incubated  with  a  proper  antibody  for  a  25 
minutes. Afterwards incubation with Dako REAL™ 
EnVision™/HRP, Rabbit/Mouse (ENV) for 25min at 
room temperature was followed by a color reaction 
using Dako REAL™ DAB+ Chromogen for 3 minutes. 
The slides were counterstained with Mayer’s hema-
toxylin. (Antibodies used for immunohistochemistry 
are listed in Supplementary Material: Table S1). 
Semi-quantitative analysis of immunohisto-
chemical staining 
For quantitative evaluation 5 areas were chosen  Journal of Cancer 2012, 3 
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after scanning the tumors sections at low power 40x. 
These fields were analyzed at 200x magnification us-
ing MicroImage software (Olympus, Japan), counting 
total stained area.  
Statistical analysis 
A  comparison  was  made  with  the 
Mann–Whitney U test. Minimal level of significance 
was defined as p < 0.05. 
Results 
Lymphatic vessels in tumor tissue 
Color lymphangiography 
Color lymphangiography pictures of tumor tis-
sue were evaluated. Only occurrence of veins and tiny 
fluid-filled intercellular microspaces was observed in 
tissue  specimens.  The  structures  that  could  corre-
spond to lymphatic vessels were not observed in tu-
mor center (Fig 1). Broadened lymphatic vessels tu-
mor could only be observed at the edge of the tumor. 
Only a few specimens showed blue dye between col-
lagen fibers. 
Immunohistochemistry 
To  identify  lymphatic  endothelium  we  used 
monoclonal  antihuman  antibodies  against:  Prox  1, 
VEGF C, VEGFR3 (flt4), Lyve1, podoplanin and also 
chemokines  and  their  receptors  CCL21  and  CCR7, 
CXCL13 and CXCR5. To distinguish blood and lym-
phatic vessels, staining for adhesion molecule CD 31 
and  v.Willebrandt  factor  was  made.  Our  study 
showed  that  Lyve1  as  well  as  VEGF  C,  were  occa-
sionally present in tumor tissue in structures without 
lumen (Fig 1). Staining did not show the presence of 
Prox1,  podoplanin  was  expressed  mainly  in  tumor 
stroma.  VEGFR3  was  expressed  in  the  vicinity  of 
cancer  nests.  Chemokine  CCL21  and  its  receptor 
CCR7 was produced by cancer cells and some stromal 
cells, but not by lymphatic endothelium. We did not 
notice  any  expression  of  CXCL13  and  its  receptor 
CXCR5. 
 
 
Figure 1. A,B,C color lymphangiography A. Vein vessels in tumor B. Lymphatic vessels from tumor edge C. Microspaces in tumor tissue 
filled with fluid. Original magnification: x100 D-I Immunostaining for D. FVIII E. Lyve-1 F. CD31 G. podoplanin H. Flt4 I. VEGF C; Original 
magnification x200.  Journal of Cancer 2012, 3 
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Figure 2. Staining for growth factors and their receptors: A. EGF, B. EGFR, C. FGF2, D.FGF7, E.IGF, F. IGFR, G HGFα, H. c-Met, I. PDGF 
B; original magnification x200 
 
Growth factors in pancreatic cancer 
25  tumor  tissues  were  studied  immunohisto-
chemically for expression of growth factors in tumor 
tissue (Fig. 2). Expression of growth factors was found 
in all cases. The immunoreactivity of EGF was weak 
to moderate in cytoplasm of cancer cells. As for EGFR 
we found its expression to be moderate to strong in 
cytoplasm  of cancer cells  and weak in small ductal 
cells. Strong FGF2 and FGF7 protein expression was 
observed  in  the  cytoplasm  and  cytoplasmic  mem-
brane  of  neoplastic  cells.  Cytoplasmic  staining  for 
IGF1 and IGF-IR was moderate to strong in cancer 
cells and positive reaction for IGF-IR was also found 
in  stromal  cells.  PDGF-BB  immunoreactivity  was 
moderate to strong in cytoplasm of cancer cells and 
also in 6 cases we found nuclear staining in cancer 
cells as well as in infiltrating immune cells. Membra-
nous and cytoplasmic staining for HGF was strong 
in tumor cells whereas staining of c-Met was moder-
ate to strong. 
Expression  of  growth  factors  was  compared 
against  tumor  grading  and  N  stage.  Using  a  semi-
quantitative estimation of all considered growth fac-
tors  expression,  the  result  of  statistical  analysis 
showed that only difference in expression between G2 
and  G3  group  was  statistically  relevant  in  case  of 
c-Met receptor (p = 0.033). Estimated mean of expres-
sion  levels  are  presented  in  table  2.  Expression  of 
FGF2, FGF7, IGF1 and HGFα was stronger at the G2 
stage of tumor. Expression of EGF, EGFR,  IGF1-R, 
PDGF and c-Met was at a higher level in G3 group. In 
relation to N stage the expression of FGF7, EGFR and 
IGF1 was lower in N1 group but no difference in ex-
pression was statistically significant. 
Table 2. Comparison of expression of growth factors. 
(NS- not significant, S-significant). 
Antigen G2  G3  Significance N0  N1  Significance 
FGF2  879,5  574,5  NS  673,76  719  NS 
FGF7  470  371,4  NS  414,55  389,88  NS 
EGF  270  456,17  NS  325,04  326  NS 
EGFR  344,04  533,28  NS  427,34  362  NS 
IGF1  509,66  435,55  NS  442,31  406,6  NS 
IGFR  561,55  719,98  NS  452,15  821,82  NS 
PDGF  362,83  370  NS  348,52  398,93  NS 
HGFα  1339,5  1014,17 NS  1113  1225  NS 
cMet  697,56  1200,39 S  823  921,52  NS  Journal of Cancer 2012, 3 
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Infiltrating inflammatory cells 
To evaluate cell infiltrates we used monoclonal 
antibodies against: CD68, HLA II, neutrophil elastase, 
CD3,  CD56.  We  found  numerous  lymphocyte  and 
macrophages infiltration. There was also a strong ex-
pression of neutrophil elastase. No NK cells infiltra-
tion was observed. Inflammatory cells were present 
around  neoplastic  glands  and  also  strongly  around 
nerves infiltrated by cancer cells (Fig.3). 
We compared the results due to N stage and we 
found that the number of macrophages in tumor tis-
sue was significantly higher in group with metastases 
to  lymph  nodes  (401)  than  in  N0  group  (167)  (p  = 
0,0085). 
Discussion 
Early lymph node metastases are distinguishing 
mark  in  pancreatic  cancer.  The  significance  of  lym-
phatic  vessels  and  lymphangiogenesis  has  been 
widely  discussed  in  recent  years 12.  Our  research 
shows that lymphangiogenesis in pancreatic cancer is 
weak and lymphatic vessels are hardly present in 
tumor tissue. Also, as was reported previously, e x-
pression of VEGF C was weak. Due to strong desm o-
plastic reaction lymphatic vessels inside tumor are 
collapsed and incapable of participation in metast a-
ses.  We found lymphatic vessels only at peripheral 
tissue surrounding cancer, not in the center of the 
tumor  lesions.  In  conclusion  we  claim  that  dense 
desmoidal tissue and lack of intratumoral lymphatics 
preclude lymphatic metastases from the tumor core. 
In  pancreatic  tumors  we  observed  intensive 
immune cells infiltration. We found that number of 
macrophages is higher in group with lymph node 
metastases. This observation s upports the statement 
about  participation of macrophages in creating m e-
tastases. In pancreatic cancer it was reported prev i-
ously that macrophages are involved in angiogen e-
sis13, supporting tumor growth and invasion of cancer 
cells. They are source of angiogenic factors like VEGF 
and also MMP9 which degrade extracellular matrix. 
Important fact is that macrophages can suppress T cell 
response. Thus, macrophages infiltrating pancreatic 
tumor are important factor in creating metastases. 
 
 
 
 
Figure 3. Characterization of the inflammatory infiltrate: A. CD3, B.CD68 macrophages, C.elastase, D. CD56; original magnification 
x200.  Journal of Cancer 2012, 3 
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Abundant expression of growth factors is typical 
for  pancreatic  cancer  tissue.  As  they  participate  in 
signaling  pathways  mediated  by  receptor  tyrosine 
kinases they might regulate cell proliferation, migra-
tion and survival. Previous studies on expression of 
growth  factors  provided  interesting  observation.  It 
was reported that high level of EGF and EGFR corre-
lated with lymph node involvement and distant me-
tastasis as well as reduced median survival14. Strong 
expression FGF2 was told to correlate with advanced 
tumor stage and increased invasiveness 15. FGF7 was 
connected with increased proliferation in pancreatic 
cancer cells but also in chronic pancreatitis-like lesions 
adjacent to cancer cells16. Also overexpression of IGF1 
and  IGF1-R  was  stated  in  pancreatic  cancer  and 
IGF1-R was suggested to be good target fo r cancer 
therapy17,18. Only in case of PDGF-BB high levels in 
blood  serum  were  favorable  prognosis 19 and  high 
expression in tumor was related to decreased pancre-
atic cancer growth 20. In our research we observed 
strong expression of growth factors, however we only 
for c-Met receptor we were able to claim statistically 
significant difference between G2 and G3 group. No 
significant  difference  was  observed  in  relation  to 
lymph node metastases. 
Our results indicate that c-Met might be pivotal 
element in pancreatic  cancer. This receptor tyrosine 
kinase is activated by HGF and physiologically they 
participate in embryonic development and also du r-
ing adult life in liver regeneration and wound hea l-
ing21. However their overexpression is observed in 
pancreatic cancer, even in early stage of carcinogene-
sis22.  
c-Met activation leads to increased proliferation, 
enhanced motility and invasion. Therefore we pr e-
sume that an increase in c-Met expression between G2 
and G3 stages indicates more aggressive phenotype 
which  might  be  re lated  to  epithelial -mesenchymal 
transition. EMT is often considered a first step to m e-
tastases as it is related to reduced E -cadherin expres-
sion  and  appearance  on  N -cadherin 23.  ―Cadherin 
switch‖ was also observed in pancreatic cancer24. De-
creased  E-cadherin  expression  was  associated  with 
advanced  stage  and  lymph  node  metastases25. An-
other factor was linked to lymph nodes involvement – 
presence of macrophages – this was also confirmed by 
our studies. Our results indicate that the amount of 
macrophages  is  significantly  higher  in  group  with 
lymph node metastases, as it was reported previous-
ly26. Recently it has been shown that macrophages 
also participate in EMT process 27. They not only e x-
press EMT- inducing cytokines but also MMP9 that 
cleaves  E-cadherin/β-catenin  complex.  Tan  et  al. 
suggested that macrophage MMP9 supports EMT also 
by disrupting of basement membrane. This is a crucial 
mechanism for increased motility and invading other 
tissues.  
Apart  from  HGF,  other  growth  factors  like 
IGF1, EGF, FGF are also able to induce EMT23. They 
are all strongly expressed in pancreatic tumor tissue 
and  their  overexpression  is  usually  associated  with 
tumor progression and poorer survival28,29. 
In  conclusion,  we  showed  two  factors  that  in-
fluence  pancreatic  cancer  progression  and  invasion: 
c-Met receptors and macrophages infiltrating tumor 
tissue. Based on our analysis, this indicates that epi-
thelial-mesenchymal transition might be crucial in the 
progression of pancreatic cancer. We intend to exam-
ine this through further research.  
Supplementary Material 
Table S1: Antibodies used for immunohistochemistry. 
http://www.jcancer.org/v03p0285s1.pdf 
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